Latent autoimmune diabetes in the elderly

Immunological and clinical characteristics of Latent Autoimmune Diabetes in the Elderly (LADE)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN99959577

Enrollment

155

Registered

2018-05-25

Start date

2014-06-01

Completion date

Unknown

Last updated

2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune and non autoimmune type 2 diabetes mellitus Nutritional, Metabolic, Endocrine Type 2 diabetes mellitus

Interventions

155 T2DM patients were randomly recruited between June 2014 and March 2017 with two principal inclusion criteria: individuals with diabetes onset over 65 years of age and a BMI under 30 kg/m2. Anthro

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. T2DM patients 2. Diabetes onset over 65 years of age 3. BMI under 30 kg/m2

Exclusion criteria

Exclusion criteria: 1. Patients with active systemic disorders and/or infections 2. Individuals with a previous diagnosis of T1DM, liver or heart failure 3. Surgery or hospitalization over the past year

Design outcomes

Primary

Measure	Time frame
The prevalence of the autoantibodies GADA, IA2A and ZnT8A, assessed by radio ligand binding assay (RBA) at a single study visit	—

Secondary

Measure	Time frame
Measured at a single study visit: 1. HbA1c, measured using high-performance liquid chromatography (HPLC) Variant II Turbo HbA1c Kit 2.0 2. Cardiovascular disease prevalence, assessed using patients clinical records of coronary heart disease, stroke, or peripheral arterial disease 3. Fasting plasma glucose (FPG), creatinine, total cholesterol, TG, LDL-C and HDL-C, measured in serum using standardized procedures by enzymatic methods 4. BMI, calculated as weight (kg)/[height(m)]2 5. Anthropometric measurements (height, weight and waist circumference), systolic blood pressure and diastolic blood pressure, determined by standardized protocols	—

Measure

Time frame

Measured at a single study visit: 1. HbA1c, measured using high-performance liquid chromatography (HPLC) Variant II Turbo HbA1c Kit 2.0 2. Cardiovascular disease prevalence, assessed using patients clinical records of coronary heart disease, stroke, or peripheral arterial disease 3. Fasting plasma glucose (FPG), creatinine, total cholesterol, TG, LDL-C and HDL-C, measured in serum using standardized procedures by enzymatic methods 4. BMI, calculated as weight (kg)/[height(m)]2 5. Anthropometric measurements (height, weight and waist circumference), systolic blood pressure and diastolic blood pressure, determined by standardized protocols

—

Countries

Argentina

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026